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ABSTrACT
Background: Stent thrombosis is the sudden occlusion of 
a stented coronary artery due to thrombus formation. Our 
objective was to identify variables associated to definite stent 
thrombosis (ST) and assess the outcomes of patients treated 
with bare-metal stents. Methods: Consecutive patients treated 
between December 2007 and August 2012 were analyzed. 
Those with ST were compared to those without ST as to 
clinical and angiographic characteristics, and early and 
late outcomes. results: Of a total of 6,495 percutaneous 
coronary interventions (PCIs), 36 cases of ST (0.55%) were 
observed, of which 18 were early (50%), 14 (38.9%) late 
and 4 (11.1%) very late ST. Patients with ST were younger, 
with a greater prevalence of chronic renal failure and acute 
coronary syndromes. ST was more frequent in bifurcation 
lesions (11% vs. 4%; P = 0.03) or lesions with visible 
thrombus at angiography (55.5% vs. 2.8%; P < 0.01). All 
patients were submitted to emergency PCI, and in the in-
hospital phase, myocardial infarction (MI) and death were 
observed in 33.3% and 16.6%, respectively. Mean follow-
up was 30.2 + 16.3 months and early discontinuation of 
dual antiplatelet therapy was observed in 6 of the 36 cases 
(16.7%). In the late follow-up target vessel revascularization 
was observed in 33.3%, MI in 20% and no additional deaths 
were observed. Conclusions: ST proved to be an event with 
high in-hospital mortality and late morbidity. The occurrence 
of this event was associated to more complex clinical and 
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rESUMO
Perfil Clínico e Evolução Tardia de Pacientes  
com Trombose de Stent Não-Farmacológico
Introdução: A trombose de stent é a oclusão súbita de uma 
artéria tratada com stent em decorrência da formação de 
trombos. Nosso objetivo foi identificar variáveis associadas à 
trombose definitiva de stent (TS) em stents não-farmacológicos 
e avaliar a evolução dos pacientes que apresentaram esse 
evento. Métodos: Foram analisados pacientes tratados con-
secutivamente entre dezembro de 2007 e agosto de 2012. 
Aqueles com TS foram comparados ao grupo sem TS quanto 
às características clínicas e angiográficas, e evoluções inicial 
e tardia. resultados: De um total de 6.495 intervenções 
coronárias percutâneas (ICPs), foram observados 36 (0,55%) 
casos de TS, sendo em 18 (50%) precoce, em 14 (38,9%) 
tardia e em 4 (11,1%) muito tardia. Pacientes com TS mostr-
aram ser mais jovens, com maior prevalência de insuficiência 
renal crônica e síndrome coronária aguda. TS ocorrereu mais 
frequentemente em lesões de bifurcação (11% vs. 4%; P = 
0,03) ou lesões com presença de trombo visível à angiogra-
fia (55,5% vs. 2,8%; P < 0,01). Todos os pacientes foram 
submetidos a ICP de emergência, sendo observados, na fase 
intra-hospitalar, infarto do miocárdio (IM) e óbito em 33,3% 
e 16,6%, respectivamente. O tempo médio de seguimento foi 
de 30,2 ± 16,3 meses e a descontinuação precoce da terapia 
antiplaquetária dupla foi verificada em 6 dos 36 casos de TS 
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angiographic characteristics and lower compliance with dual 
antiplatelet therapy.
 
 
 
 
 
DESCrIPTOrS: Coronary thrombosis. Angioplasty. Stents
The present study included all patients that were 
treated at this institution for ST with bare-metal stents 
(BMS), and compared their clinical, angiographic, and 
procedural characteristics with the characteristics of 
cases without ST. Patients treated with drug-eluting 
stents (DES) were excluded, as they represented a mi-
nority of this population, and because they comprised 
part of research protocols that did not always include 
PCI in everyday clinical practice, which was the aim 
of this analysis.
Definitions
ST is defined, according to the Academic Research 
Consortium (ARC),1 as the angiographic confirmation of 
the presence of a thrombus that originated inside the 
stent or in the segment surrounding the 5 mm proximal 
or distal to the stent, and that was associated with at 
least one of the following criteria within a 48-hour time 
window: acute ischemic symptoms at rest; new ischemic 
alterations on ECG; typical increases and decreases in 
markers of myocardial necrosis; and the presence of 
an occluding or non-occluding thrombus. ST was also 
defined through the pathological confirmation of a recent 
thrombus within the stent during autopsy or through 
the analysis of tissue removed during thrombectomy. 
ST was also classified according to the time of oc-
currence after stent implantation, as acute (24 hours), 
subacute (> 24 hours to 30 days), late (> 30 days to 
one year), or very late (>  one year). The acute and 
subacute cases of ST were grouped together as early 
stent thrombosis.1
Periprocedural MI was defined by an increase in 
the biomarker creatine phosphokinase MB-fraction of > 
three times the normal upper limit in a test performed at 
48 hours post-procedure.1 Major adverse clinical events 
(MACEs) were defined by the combined outcomes of 
death from any cause, MI, and emergency heart surgery. 
Angiographic success was defined by the achievement of 
Thrombolysis in Myocardial Infarction (TIMI) flow grade 
3, absence of a thrombus, dissection or perforation with 
active extravasation of contrast material, and residual 
stenosis < 20% (quantitative coronary angiography) in the 
treated segment at the end of the procedure. Procedural 
success was defined as angiographic success, together with 
the absence of MACEs during the index hospitalization.
S tent thrombosis (ST) is the sudden occlusion of an artery treated with a stent due to thrombus formation, which presents, in most patients, as sudden death 
(in approximately 20% to 40% of cases), myocardial 
infarction (MI) (in approximately 50% to 70%), or the 
need for revascularization.1-8
Despite the development of better stenting tech-
niques, and more effective and more potent antiplate-
let therapy, ST continues to occur in 1% to 2% of 
elective cases and in up to 5% of patients with acute 
coronary syndrome.3,6,9-12 Several observational studies 
have identified a number of clinical, angiographic, 
and procedure-related risk factors associated with the 
occurrence of ST, contributing to the identification of 
at-risk populations and the use of preventive measures 
against these events.3,6,9-11,13
As a result of myocardial ischemia caused by the 
sudden occlusion of an epicardial vessel by a thrombus, 
emergency revascularization by percutaneous coronary 
intervention (PCI) is the treatment of choice to restore 
vessel patency. Manual thrombus aspiration is an 
attrac tive option that is associated with higher rates 
of myocardial reperfusion. Emergency coronary artery 
bypass graft (CABG) surgery is required in a minority 
of cases (< 10%) when recanalization of the occluded 
vessel cannot be achieved.1
The present study aimed to identify the clinical and 
angiographic variables and to assess the late evolution 
of patients with ST treated at a tertiary hospital in the 
public healthcare network of the state of São Paulo. 
MethoDs
study design and population
A retrospective data analysis was performed of 
patients treated in the Invasive Cardiology Department 
of Instituto Dante Pazzanese de Cardiologia (São Paulo, 
SP, Brazil) from December 2007 to August 2012. Dur-
ing this period, the clinical and angiographic data, 
as well as those related to procedural and in-hospital 
evolution were prospectively collected and stored in a 
dedicated electronic database, according to a pre-es-
tablished protocol, for all patients undergoing elective 
or emergency PCI.
(16,7%). Na evolução tardia observou-se revascularização do 
vaso-alvo em 33,3%, IM em 20% e nenhum óbito adicional. 
Conclusões: A TS mostrou ser evento com elevada mortali-
dade hospitalar e alta morbidade tardia. A ocorrência desse 
evento foi associada a características clínicas e angiográficas 
de maior complexidade e a menor aderência à terapêutica 
antiagregante dupla.
 
DESCrITOrES: Trombose coronária. Angioplastia. Stents.
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The diagnosis of renal failure was established in 
patients with creatinine clearance < 60 mL/min/1.73 m2.
Procedure
The PCI procedures were performed according to 
the current guidelines, aiming for optimal angiographic 
results after coronary device implantation.14 The choices 
of arterial access route, the material used in the PCI 
(guidewire and balloon catheter, among others), the 
type of stent used, the stent implantation technique, 
and the adjunctive medical therapy were at the sur-
geon’s discretion. Regarding antithrombotic therapy, 
the pre-treatment included acetylsalicylic acid, at a 
dose of 100 mg/day in cases of chronic use (> seven 
days) or at a loading dose of 200 mg administered 
> 24 hours prior to PCI, and clopidogrel, at a loading 
dose of 300 mg > 24 hours before the intervention 
or 600 mg before the procedure (preferably > two 
hours) in patients with acute coronary syndrome. 
After the procedures, the patients were instructed 
to maintain dual antiplatelet therapy (acetylsalicylic 
acid 100 mg and clopidogrel 75 mg) for at least one 
month in cases of BMS placement, and for one year 
for DES. Regarding antithrombin therapy during the 
procedure, heparin was administered intravenously 
at a dose of 70 U/kg to 100 U/kg of body weight to 
maintain activated clotting time > 250 seconds, or > 
200 seconds in cases of concomitant administration 
of glycoprotein IIb/IIIa inhibitors, prescribed at the 
surgeon’s discretion. 
Complementary examinations were conducted ac-
cording to the institutional protocol, and they included 
12-lead electrocardiography before, immediately after 
and once daily after the procedure until hospital dis-
charge. The laboratory tests included analysis of cardiac 
biomarkers pre-procedure, at the first 24 hours post-
procedure, and once daily until hospital discharge.
Angiographic analysis 
Qualitative and quantitative angiographic analyses 
were performed before and after the procedures. A 
qualitative assessment was performed in accordance with 
the criteria used for American College of Cardiology/
American Heart Association (ACC/AHA) classification.15 
Lesions were considered as type C when they had at 
least one of the following characteristics: extension > 
20 mm (diffuse injury); significant tortuosity (three or 
more angles > 75° in the segment proximal to the le-
sion); significant lesion angulation (> 90°); bifurcation 
lesions with the inability to protect the side branch with 
a guidewire; degenerated saphenous vein graft lesions; 
and chronic occlusion (> three months). The analysis of 
quantitative coronary angiography was performed of-
fline by experienced professionals, using validated and 
commercially available software (QAngio XA, release 
7.3 – Medis Medical Imaging Systems BV – Leiden, the 
Netherlands). Lesion extent was defined by the distance 
between points immediately before and after the target 
stenosis was considered as free of atheromatous disease, 
that is, the transition between the stenotic segment and 
the normal reference. The minimal luminal diameter 
(MLD) and the reference vessel diameter (RVD) were 
used to calculate the stenosis diameter (SD) using the 
following formula: SD (%) = (1 – [MLD/RVD]) × 100. 
Immediate gain was defined as the pre- and post-
procedure difference in MLD (post-procedure MLD 
– pre-procedural MLD). Quantitative variables were 
reported in the intrastent and intra-segment segments, 
which included the intrastent segment combined with 
the 5-mm borders in the peristent regions, according 
to the previously described methodology.
statistical analysis
For comparative purposes, the total population was 
divided into two groups, according to the presence or 
absence of thrombosis, aiming to identify factors as-
sociated with this adverse event. Qualitative variables 
were expressed as absolute frequencies and percentages 
and were compared by the chi-squared test or Fisher’s 
exact test, as appropriate. The quantitative variables are 
expressed as the means and standard deviations and 
were compared using Student’s t-test. A p-value < 0.05 
was considered significant. 
Results
Of the total of 6,495 PCIs with BMS performed 
during the study period, there were 36 (0.55%) cases of 
ST, with 18 (50%) early (acute or subacute), 14 (38.9%) 
late, and four (11.1%) very late events.
Patients with ST were younger (58.6 ± 11.4 years 
old vs. 63.7 ± 11.9 years old; P < 0.01) and had a 
higher prevalence of previous PCI (100% vs. 14.1%; 
P < 0.01), chronic renal failure (41.7% vs. 28%; P < 0.01), 
and procedures performed in the presence of acute 
coronary syndrome when compared to patients without 
ST. There were no differences between the groups 
regarding gender, comorbidities, or the prevalence of 
risk factors for atherosclerosis (Table 1).
ST occurred more frequently in bifurcation lesions 
(11% vs. 4%; P = 0.03) and in lesions with visible 
thrombi on angiography (55.5% vs. 2.8%; P < 0.01) 
(Table 2). ST also tended to occur more often in lesions 
located in degenerated saphenous vein grafts (11% vs. 
4.5%; P  =  0.06) and in lesions > 20 mm (66.7% vs. 
51.3%; P = 0.07). 
Table 3 presents the results of the quantitative 
coronary angiography analysis of patients with ST.
Among the patients with ST, the mean clinical 
follow-up duration was 30.2 ± 16.3 months. Early 
discontinuation of dual antiplatelet therapy (< one 
month for BMS) was observed in six of the 36 cases 
of ST (16.7%).
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Table 1 
Basal clinical characteristics
Variable
With ST
(n = 36)
Without ST  
(n = 6,495) P-value
Age, years 58.6 ± 11.4 63.7 ± 11.9 < 0.01
Female gender, n (%) 14 (38.9) 2,020 (31.3) 0.33
Systemic arterial hypertension, n (%) 30 (83.3) 5,524 (85.5) 0.73
Dyslipidemia, n (%) 22 (61.1) 4,360 (67.5) 0.45
Current smoking, n (%) 10 (27.8) 1,214 (19.2) 0.15
Diabetes, n (%) 13 (36.1) 2,002 (31) 0.51
Insulin use 2 (5.6) 221 (3.4) 0.48
Family history of CAD, n (%) 3 (8.3) 625 (9.7) 0.79
Previous PCI, n (%) 36 (100) 904 (14.1) < 0.01
Previous CABG, n (%) 1 (2.8) 258 (4) 0.71
Previous stroke, n (%) 1 (28) 137 (2.1) 0.79
Renal failure, n (%) 15 (41.7) 1,806 (28) < 0.01
COPD, n (%) 1 (2.8) 123 (1.9) 0.83
Clinical picture, n (%) < 0.01
ACSNSTE 12 (33.3) 1,155 (17.9)
ACSSTE 18 (50) 688 (10.7)
Stable angina 6 (16.7) 3,025 (46.8)
Asymptomatic/ischemic equivalent 0 1,591 (24.6)
ST, stent thrombosis; CAD, coronary artery disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft surgery; 
COPD, chronic obstructive pulmonary disease; ACSSTE, acute coronary syndrome with ST-segment elevation; ACSNSTE, acute coronary 
syndrome without ST-segment elevation.
Table 2 
Angiographic characteristics
Variable
With ST
(n = 36)
Without ST
(n = 6,495) P-value
Target vessel, n (%) 0.7
ADA 19 (52.7) 3,068 (47.5)
Cx 6 (16.7) 1,434 (22.2)
RCA 11 (30.6) 1,957 (30.3)
Lesion location, n (%) 0.79
Ostial/proximal 18 (50) 3,029 (46.9)
Medium 14 (39) 2,848 (44.1)
Distal 4 (11) 582 (9)
Type C lesion, n (%) 16 (44.4) 3,294 (51) 0.43
Bifurcation lesion, n (%) 4 (11) 258 (4) 0.03
Lesion > 20 mm, n (%) 24 (66.7) 3,313 (51.3) 0.07
Vessel < 2.5 mm, n (%) 10 (27.8) 2,009 (31.1) 0.67
Visible thrombus, n (%) 20 (55.5) 183 (2.8) < 0.01
Degenerated saphenous vein graft, n (%) 4 (11) 291 (4.5) 0.06
Moderate to severe calcification, n (%) 14 (39) 2,693 (41.7) 0.73
ST, stent thrombosis; ADA, anterior descending artery; Cx, circumflex artery; RCA, right coronary artery.
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the first month. The first reports of late ST with BMS 
appeared only after the recognition of late thrombosis 
with brachytherapy.16,17 Wenaweser et al.17 demonstrated, 
in one of the largest series of patients treated with 
BMS, that ST occurred in 1.6% of cases; it was acute 
in 11%, subacute in 64%, and late in 25% of patients. 
ST is a complex phenomenon, and its etiology is 
multifactorial. According to some studies,3,13,18,19 early 
discontinuation of dual antiplatelet therapy (< one 
month for BMS) is one of the most important factors 
associated with ST. Iakovou et al.3 demonstrated, in 
patients treated with drug-eluting stents, that the most 
important independent predictor of ST was the premature 
discontinuation of antiplatelet therapy (hazard ratio [HR] 
= 89.78; 95% confidence interval [95% CI] = 29.9 to 
269.6), followed by renal failure (HR 6.49; 95% CI = 
2.6 to 16.15), bifurcation lesions (HR 6.42; 95% CI = 
2.93 to 14.07), diabetes (HR 3.71, 95% CI = 1.74 to 
7.89), and ejection fraction (HR 1.09; 95% CI = 1.05 
to 1.36 for every 10% reduction).
Renal failure is associated with increased mortality, 
despite a successful PCI.20-22 Renal failure is associated 
with metabolic and microcirculatory abnormalities, which 
can predispose the patient to thrombus formation.23,24 
Regarding bifurcation lesions, histopathology studies 
have suggested that the locations of arterial branching 
All patients were submitted to emergency PCI; du-
ring the in-hospital phase, the incidences observed of 
periprocedural myocardial infarction, contrast-induced 
nephropathy and death were 33.3%, 22.2% and 16.6% 
of cases, respectively (Table 4). During the late fol low-up 
period, target-vessel revascularization was observed 
in 33.3% of cases, which was achieved by CABG in 
most cases. A new MI was observed in six (20%) cases, 
two resulting from recurrent ST. No additional deaths 
were observed.
Discussion
The main findings of the present study were: ST 
after BMS implantation occurred in the late phase 
(> 30 days) in 50% of cases; early discontinuation of 
dual antiplatelet therapy was observed in one-sixth of 
patients with ST; the presence of renal failure, bifurca-
tion lesions, or evident thrombus on angiography, and 
of long lesions or of lesions located in degenerated 
saphenous vein grafts was more frequent in patients 
with ST; and in-hospital mortality in this population 
was high (16.7%), as was the incidence of new MACEs 
during the late clinical follow-up period.
Historically, ST in BMS has been an event that 
occurs more frequently during the initial days after 
surgery, and, by definition, has not been reported after 
Table 3 
Quantitative coronary angiography of cases  
with coronary stent thrombosis
Variable n = 36
Pre-procedure
Reference vessel diameter, mm 2.9 ± 0.7
Minimal luminal diameter, mm 0.55 ± 0.51
Stenosis diameter, % 84.1 ± 11.8
Lesion extent, mm 21.1 ± 7.2
Post-procedure
Reference vessel diameter, mm 3.2 ± 0.6
Intra-segment
 – Minimal luminal diameter, mm 2.37 ± 0.53
 – Stenosis diameter, % 24.1 ± 26.8
 – Immediate gain, mm 1.89 ± 0.62
Intrastent
 – Minimal luminal diameter, mm 2.7 ± 0.46
 – Stenosis diameter, % 14.1 ± 6.7
 – Immediate gain, mm 1.89 ± 0.53
Table 4 
In-hospital and late clinical follow-up of cases  
with coronary stent thrombosis
Variable
In-hospital n = 36
Mean hospitalization time, days 6.3
MI, n (%) 12 (33.3)
Death, n (%) 6 (16.6)
CIN, n (%) 8 (22.2)
Late n = 30
Time of follow-up (months) 30.2 ± 16.3
MI, n (%) 6 (20)
TVR, n (%) 10 (33.3)
 – PCI 2 (6.7)
 – CABG 8 (27)
Death, n (%) 0
MI, myocardial infarction; CIN, contrast-induced nephropathy; 
TVR, target vessel revascularization; PCI, percutaneous 
coronary intervention; CABG, coronary artery bypass graft.
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have low shear regions and low speed flow, predispo-
sing the vessels to the development of atherosclerotic 
plaques and thrombi.25-27
study limitations
The limitations of the present study include the 
retrospective analysis of the data from two cohorts with 
non-adjusted clinical variables and the performance of 
the study in a single centre. Additionally, only indivi-
duals with ST treated at this institution were included, 
which may have resulted in the underestimation of the 
true incidence.
conclusions
In this contemporary real-world experience, ST 
was shown to be an event with high rates of hospital 
mortality and late morbidity. As demonstrated by other 
studies, the occurrence of this event was associated 
with clinical and angiographic characteristics of greater 
complexity, and with lower adherence to the prescribed 
antiplatelet therapy.
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